Home>Topics>Stocks>Acorda Therapeutics

Acorda Therapeutics ACOR

  1. All
  2. Commentary
  3. Stock Reports
  4. Headlines
    1. We're Boosting Biogen Idec's Fair Value Estimate Following European Approval of Fampyra

      Commentary

      Wed, 27 Jul 2011

      this week. Fampyra, which is marketed in the United States under the trade name Ampyra by the firm's partner Acorda Therapeutics ACOR , is the first approved treatment to improve walking in patients with multiple sclerosis. Fampyra now marks

    2. Acorda shares soar on possible patent extension

      Headlines

      Thu, 14 Apr 2011

      BOSTON (Reuters) - Shares of Acorda Therapeutics Inc jumped 27 percent on Thursday before being halted amid optimism the company will be granted a patent extension on its multiple sclerosis drug...

    3. Elan's 2010 Results In Line; Enthusiasm for Growth Potential Tempered by High-Risk Pipeline

      Commentary

      Tue, 8 Feb 2011

      EDT) were flat, as patent expirations on older products countered strong manufacturing and royalty revenue from Ampyra, Acorda and Biogen-Idec's BIIB new oral MS drug. Tysabri's net new-patient adds actually fell in the fourth quarter, as compared

    4. Tysabri Carries Elan in 2Q

      Commentary

      Thu, 22 Jul 2010

      exploring the possible sale of this business. Royalties on Acorda 's ACOR recently approved multiple sclerosis drug Ampyra will be key to EDT's future growth, and Acorda 's second-quarter results in August will give us a

    5. New Morningstar Analyst Report - Biogen Idec, Inc.

      Stock Reports

      Tue, 30 Mar 2010

      research and development pipeline to support long - term growth . We're most optimistic about the potential of Ampyra ; Acorda ACOR received FDA approval for the novel MS drug in January , and Biogen has acquired international rights . We think Biogen

    6. Biogen to Benefit From Reduced Tysabri Uncertainty

      Commentary

      Tue, 9 Feb 2010

      reduce the probability of a worst-case outcome in our scenario-weighted fair value estimate as a result. Acorda Therapeutics ACOR received FDA approval of Ampyra in January, and Biogen also filed for European approval of the drug last month

    7. Tysabri uncertainty and recent pipeline disappointments will challenge Biogen.

      Stock Reports

      Thu, 5 Nov 2009

      optimistic about the potential of novel MS drug fampridine--for which Biogen acquired international rights from partner Acorda ACOR --to complement Biogen's existing MS franchise, as well as the potential for a next-generation version of Avonex

    8. BioMarin Records Profitable 3Q

      Commentary

      Thu, 29 Oct 2009

      We're also intrigued by the drug's potential in multiple sclerosis as a competitor to Biogen Idec's BIIB and Acorda 's ACOR similar drug candidate, fampridine, but we think it's too early to assume its safety profile will allow it to

    9. Biogen's 3Q Solid, but Pipeline Outlook Mixed

      Commentary

      Tue, 20 Oct 2009

      European approval of the drug in early 2010, and an FDA advisory committee recently gave a positive review of partner Acorda 's ACOR application in the U.S. However, we think Biogen's decision to return $1 billion of its $3 billion cash balance

    10. Biogen Sees Tysabri Revival in 2Q

      Commentary

      Thu, 16 Jul 2009

      Avonex, which will likely prove more convenient than Avonex, in our opinion. The recent collaboration with Acorda Therapeutics ACOR relating to novel MS drug candidate fampridine opens up a new group of patients for Biogen (those with more

    Content Partners